Toronto, Canada – May 20, 2025 — AI/ML Innovations Inc. (“AIML” or the “Company”) (CSE: AIML; OTCQB: AIMLF; FWB: 42FB) today announced the establishment of its Medical Advisory Board, composed of leading cardiovascular experts who will steer the clinical direction, trial design, and real‑world deployment of the Company’s flagship AI platforms MaxYield™and CardioYield™.
Members of the inaugural Medical Advisory Board include:
Dr. Paul Dorian, MD, MSc, FRCPC, FACC — Professor of Medicine, University of Toronto; Staff Cardiologist, Division of Cardiology, St. Michael’s Hospital
Dr. Alan Rabinowitz, MBChB, FRCPC, FACC — Chief Medical Officer, AIML; Cardiologist and formerly Director of the Coronary Care Unit, St. Paul's Hospital Heart Centre/ Center for Heart Lung Innovation; Clinical Associate Professor, Division of Cardiology, University of British Columbia
Dr. Brett Heilbron, MBChB, FRCPC, FACC — Medical Director, Electrodiagnostics Program; Clinical Associate Professor, Division of Cardiology, University of British Columbia; St. Paul’s Hospital Heart Centre, Vancouver, BC
Dr. Marc Deyell, MD MSc FHRS FCCS — Clinical Professor, University of British Columbia; Director, Heart Rhythm Services, St. Paul’s Hospital
Dr. Saul Isserow, MBBCh, FRCP(C), FACC — Director, Cardiology, UBC Hospital; Director, Sports Cardiology BC
Dr. Kim Connelly, MBBS, PhD, FRACP, FRCPC — Professor of Medicine and Physiology, University of Toronto; Cardiologist and Scientist, St. Michael’s Hospital
Peter Kendall, President and Chief Commercialization Officer, will serve as Chair of the Medical Advisory Board, ensuring a strong bridge between clinical insight and AIML’s commercialization strategy. With more than two decades of experience leading go-to-market programs for breakthrough health technologies, Peter is uniquely positioned to translate scientific and clinical guidance into scalable solutions. Under his leadership, the Board’s recommendations will be integrated into AIML’s core operations—ensuring that clinical guidance translates directly into product development, regulatory strategy, and commercial execution.
Paul Duffy, Executive Chairman and CEO of AIML comments. “The launch of our Medical Advisory Board reinforces AIML’s commitment to marrying world‑class science with advanced AI.Together, we will set new standards for AI‑enhanced cardiac diagnostics.”
Peter Kendall – Chair, Medical Advisory Board; President & CCO, AIML says “Uniting this calibre of clinical expertise ensures our product roadmap remains grounded in frontline insight. Their guidance will be invaluable as we expand licensing and regulatory pathways.”
AIML remains steadfast in its mission to deliver breakthrough solutions at the intersection of artificial intelligence and human health.
For more information about AIML:
For detailed information please see AIML's website or the Company's filed documents at www.sedarplus.ca.
Contact:
Blake Fallis
(778) 405-0882
info@aiml-innovations.com
About AIML Innovations Inc.
https://www.aiml.health/
AIML Innovations Inc. is a global technology company pioneering the use of artificial intelligence and neural networks to transform digital health. Our proprietary platforms leverage advanced signal processing and deep learning to convert complex biometric data into actionable clinical insights —supporting earlier diagnosis, personalized treatment, and more effective care.
With a growing portfolio of regulatory filings, including a 510(k) premarket notification and a registered FDA Device Master File, AIML is committed to rigorous validation and broad interoperability.
AIML’s shares trade on the Canadian Securities Exchange (CSE: AIML), the OTCQB Venture Market (AIMLF), and the Frankfurt Stock Exchange (42FB).
On behalf of the Board of Directors:
Paul Duffy, Executive Chairman and CEO
Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.
Forward Looking Statements – Certain information set forth in this news release may contain forward-looking statements that involve substantial known and unknown risks and uncertainties, including risks associated with the implementation of the Company's products and services as currently proposed or at all. These forward-looking statements are subject to numerous risks and uncertainties, certain of which are beyond the control of the Company, including with respect to the nature and timing of future operations and the receipt of all applicable regulatory approvals. Readers are cautioned that the assumptions used in the preparation of such information, although considered reasonable at the time of preparation, may prove to be imprecise and, as such, undue reliance should not be placed on forward-looking statements.